Preterm Delivery Clinical Trial
Official title:
The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study
The purpose of this study is whether Bryophyllum is more effective and has less side effects than traditional labor inhibitors in preventing preterm delivery.
Preterm delivery (delivery before 37 +0 weeks of gestation) is still the leading cause of
perinatal mortality and morbidity in the western countries. Due to this fact it is only
possible to achieve the mortality rate of 5‰, aspired by WHO, by an effective decrease of the
current preterm delivery rate.
An exact ascertainment of the etiology of preterm delivery is hardly possible, because
multiple, partly overlapping or multifactorial etiologies exist. Various pathologies (e.g. of
the placenta, fetus uterus or endocrine dysfunctions) may lead to preterm deliveries or
preterm contractions.
Traditional diagnostic tools for preterm contractions/preterm deliveries has consisted of
clinical examinations (digital palpation of the cervix) and the recording of the contractions
by the tocogram. Both methods have a low sensitivity and predictive values. Furthermore the
clinical examination has a high interobserver variability of 29%.
With the introduction of transvaginal sonographic measurements, the sensitivity for preterm
deliveries could substantially be elevated.
Despite intensive efforts in the field of preventive care, screening and therapeutic
interventions (e.g. the use of tocolytics), the incidence of preterm deliveries has remained
stable for over two decades.
For inhibiting labor, beta-mimetics has been utilised for over 20 years. Beta mimetics are
currently able to prevent preterm labor in average for approximately 48 hours. Other
medicaments with tocolytic properties include calcium antagonists, prostaglandin inhibitors
and currently, antagonists of the oxytocic receptor.
However, conventional labor inhibitors show considerable side effects, such as cardiovascular
effects (e.g.tachycardia) or tremor in case of beta mimetics.
Due to the stagnant long-term results of the conventional labor inhibitors, we are looking
for alternative medicaments, especially with a lower side effect profile.
The phytopharmacon Bryophyllum, which is produced from the leaves of Bryophyllum pinnatum, is
available as a 5% aqueous tincture, 33% dilution or 50% trituration.
Bryophyllum has been used since 1970 for tocolysis, either orally or intravenously. However,
because of its predominant use in anthroposophical clinics, clinical trials for its
evaluation has been rarely performed. Currently, in vitro studies endorsed the inhibition of
myometrial contractibility. In contrast to conventional labor inhibitors, side effects has
been only occasionally observed in case of Bryophyllum (e.g. skin irritation).
To evaluate the tocolytic effects of orally applicated Bryophyllum versus Placebo in case of
patients with preterm contractions, twin pregnancies and patients with a risk for preterm
delivery, due to previous preterm contractions/preterm deliveries.
Bryophyllum or Placebo will be given prophylactic or, parallel with conventional labor
inhibitors in case of preterm contractions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03304782 -
Fitbit Activity Tracker to Predict Risk of Preterm Birth
|
||
Recruiting |
NCT02420743 -
Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
|
||
Completed |
NCT01119963 -
Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
|
Phase 2/Phase 3 | |
Completed |
NCT01665378 -
Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes
|
N/A | |
Completed |
NCT00141908 -
Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate
|
Phase 2 | |
Recruiting |
NCT05278130 -
Serial Screening and Treatment of Bacterial Vaginosis Trial
|
N/A | |
Terminated |
NCT03596125 -
Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)
|
Phase 2/Phase 3 | |
Recruiting |
NCT03123926 -
Spontaneous Preterm Birth Marker Test
|
N/A | |
Completed |
NCT00201643 -
A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
|
Phase 4 | |
Completed |
NCT01353807 -
Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health
|
N/A | |
Terminated |
NCT02545127 -
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
|
Phase 2 | |
Completed |
NCT02371356 -
Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
|
||
Active, not recruiting |
NCT01009723 -
Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers
|
N/A | |
Completed |
NCT00883324 -
Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum
|
N/A | |
Completed |
NCT00615550 -
PREGNANT Short Cervix Trial
|
Phase 3 | |
Completed |
NCT02694679 -
Randomized Controlled Trial of Social Network Targeting in Honduras
|
N/A | |
Completed |
NCT01031017 -
Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies
|
Phase 4 | |
Completed |
NCT00331695 -
Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery
|
Phase 4 | |
Completed |
NCT00329914 -
Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?
|
Phase 2 | |
Completed |
NCT01818518 -
Neonatal Outcome by Reason for Delivery
|